Kezar Life Sciences, Inc. (NASDAQ: KZR) related to its sale to Aurinia Pharmaceuticals Inc. Under the terms of the proposed transaction, Kezar shareholders are expected to receive $6.955 per share in cash and one non-transferable contingent value right.